View this email in your browser ([link removed])
[link removed]
The Biosimilar Discount: Growing Biosimilar Market Share Is Driving Down Prices For Expensive Biologic Medicines
NEW BRIEF | June 11, 2024
From 2019-2023, patients saved $15 billion from biosimilar competition. Had there been competition during the same period for two other biologics, Humira and Enbrel, patients would have saved another $13 billion, for a total of $28 billion.
Read here . . . ([link removed])
How the FDA's Sunscreen Skepticism Burns Americans
Forbes | Sally Pipes | June 10, 2024
Every day, nearly 10,000 ([link removed]) people in the United States are diagnosed with skin cancer.
The good news is that applying sunscreen can substantially reduce a person’s risk of getting skin cancer. The bad news is that the federal government is doing its best to keep effective sunscreens out of the hands of ordinary Americans.
Read more... ([link removed])
------------------------------------------------------------
Why Next President Needs to Scrap Enhanced Subsidies
Newsmax | Sally Pipes | June 10, 2024
The Affordable Care Act’s defenders are sounding the alarm over the health law’s future under a possible second Trump presidency.
The conventional wisdom suggests that, should Donald Trump win in November, the enhanced premium subsidies signed into law by President Joe Biden would be allowed to expire ([link removed]) on December 31, 2025.
Read more... ([link removed])
[link removed]
============================================================
** Twitter ([link removed])
** Facebook ([link removed])
** YouTube ([link removed])
** LinkedIn ([link removed])
** Instagram ([link removed])
** Website ([link removed])
Copyright © 2024 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.
Our mailing address is:
P.O. Box 60485 Pasadena, CA 91116
** ([link removed])
Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.
